AUPN842196A0 - New compound - Google Patents

New compound

Info

Publication number
AUPN842196A0
AUPN842196A0 AUPN8421A AUPN842196A AUPN842196A0 AU PN842196 A0 AUPN842196 A0 AU PN842196A0 AU PN8421 A AUPN8421 A AU PN8421A AU PN842196 A AUPN842196 A AU PN842196A AU PN842196 A0 AUPN842196 A0 AU PN842196A0
Authority
AU
Australia
Prior art keywords
new compound
compound
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPN8421A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AUPN8421A priority Critical patent/AUPN842196A0/en
Publication of AUPN842196A0 publication Critical patent/AUPN842196A0/en
Priority to ZA971669A priority patent/ZA971669B/en
Priority to AU22306/97A priority patent/AU2230697A/en
Priority to JP9531648A priority patent/JP2000506850A/en
Priority to PCT/JP1997/000571 priority patent/WO1997032858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
AUPN8421A 1996-03-05 1996-03-05 New compound Abandoned AUPN842196A0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AUPN8421A AUPN842196A0 (en) 1996-03-05 1996-03-05 New compound
ZA971669A ZA971669B (en) 1996-03-05 1997-02-26 A condensed heterocyclic compound and a salt thereof which have medical uses
AU22306/97A AU2230697A (en) 1996-03-05 1997-02-27 Quinoxaline derivatives as glutamate receptor antagonists
JP9531648A JP2000506850A (en) 1996-03-05 1997-02-27 Quinoxaline derivatives as glutamate receptor inhibitors
PCT/JP1997/000571 WO1997032858A1 (en) 1996-03-05 1997-02-27 Quinoxaline derivatives as glutamate receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN8421A AUPN842196A0 (en) 1996-03-05 1996-03-05 New compound

Publications (1)

Publication Number Publication Date
AUPN842196A0 true AUPN842196A0 (en) 1996-03-28

Family

ID=3792733

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPN8421A Abandoned AUPN842196A0 (en) 1996-03-05 1996-03-05 New compound

Country Status (4)

Country Link
JP (1) JP2000506850A (en)
AU (1) AUPN842196A0 (en)
WO (1) WO1997032858A1 (en)
ZA (1) ZA971669B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304404A (en) 1998-06-01 2001-07-18 盐野义制药株式会社 Cyanoiminoquinoxaline derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
JP4707261B2 (en) * 2001-05-15 2011-06-22 日本エンバイロケミカルズ株式会社 Quinoxaline compound and industrial bactericidal composition
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302304D0 (en) * 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
EP2374802B1 (en) 2008-11-10 2014-04-23 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
EP2241557A1 (en) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses
EP2473498A1 (en) * 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
TWI535442B (en) 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
US9067923B2 (en) 2011-11-09 2015-06-30 Kyowa Hakko Kirin Co., Ltd. Substituted quinoxalines
CN105143187B (en) 2013-02-28 2018-04-03 武田药品工业株式会社 The method for preparing sulfonyl chloride compound
MX2017016413A (en) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
JP6165373B1 (en) * 2017-02-24 2017-07-19 タマ化学工業株式会社 Method for producing pyridine-3-sulfonyl chloride
WO2023042888A1 (en) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
WO2023042887A1 (en) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Pharmaceutical composition for use in treating cognitive decline, excess weight, or obesity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
CA2180122A1 (en) * 1994-01-03 1995-07-13 Sui Xiong Cai 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the usethereof as antagonists for the glycine/nmda receptor
AU688459B2 (en) * 1994-04-08 1998-03-12 Shionogi & Co., Ltd. Oxopyridinylquinoxaline derivative

Also Published As

Publication number Publication date
WO1997032858A1 (en) 1997-09-12
JP2000506850A (en) 2000-06-06
ZA971669B (en) 1998-07-27

Similar Documents

Publication Publication Date Title
AU5703398A (en) Novel compounds
AU2845197A (en) Cycloalkano-pyridines
AU4578297A (en) New combination
AU2684197A (en) Handleset
AUPN842196A0 (en) New compound
AU4925697A (en) Compounds
AUPN955596A0 (en) New compound
AU2090897A (en) Hydroxyhexahydropyridazines
AU3620297A (en) Substituted triazoloazinesulphonamides
AU3130597A (en) Tristetraprolin
AU5423298A (en) Novel compounds
AU3771497A (en) Substituted p-trifluoromethylphenyluracils
AUPO381496A0 (en) New compound
AUPO062696A0 (en) Novel compounds
AU1926397A (en) Substituted 1-methyl-3-benzyluracils
AU1900097A (en) Cremators
AU2237197A (en) Fishing-lure
AUPO440596A0 (en) New compound
AUPO691897A0 (en) New compound
AU3711697A (en) Novel compounds
AUPO371596A0 (en) New compound
AU2895097A (en) New thiazolopyridines
AU2955597A (en) Substituted phenyluracils
AU1597197A (en) Thienoquinolines
AU4641497A (en) Novel compounds